panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT05198934
- Locations
- 🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇺🇸Kelsey Research Foundation, Houston, Texas, United States
🇺🇸Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Inflammatory CarcinomaInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05177796
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
- Conditions
- Digestive CancerColon CancerPancreas Cancer
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Anup Kasi
- Target Recruit Count
- 50
- Registration Number
- NCT05121038
- Locations
- 🇺🇸
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸The University of Kansas Medical Center, North Kansas City, Missouri, United States
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- Conditions
- Castration-resistant Prostate CancerNon-small Cell Lung CancerColorectal Cancer
- Interventions
- Drug: FOLFIRI Protocol
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05084859
- Locations
- 🇺🇸
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham, North Carolina, United States
🇺🇸UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Single photon emission computed tomography/computed tomography (SPECT/CT) scans
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 28
- Registration Number
- NCT04840472
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 214
- Registration Number
- NCT04787341
- Locations
- 🇮🇹
U.O. Oncologia 2 Universitaria, Pisa, PI, Italy
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 71
- Registration Number
- NCT04587128
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 151
- Registration Number
- NCT04425239
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
Lymph Node Ratio and Kras Mutation in R Colon Cancer
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 433
- Registration Number
- NCT04342676
- Locations
- 🇪🇬
Mansoura University Oncology Center, Mansoura, Ad Daqahliyah, Egypt
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04234594
- Locations
- 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.